The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
SARS‐CoV‐2
In article number 2311537 by Jincun Zhao, Xun Sun, and co‐workers, a specific ACE2‐binding peptide with a superior antiviral activity was identified and used to modified the inhaled nanoemulsions. The inhaled remdesivir nanoemulsions strongly inhibit SARS‐CoV‐2 not only by blocking the binding of virus to host cells at the cell surface but also restricting virus replication intracellularly...
Three kinds of coronaviruses are highly pathogenic to humans, and two of them mainly infect humans through Angiotensin‐converting enzyme 2 (ACE2)receptors. Therefore, specifically blocking ACE2 binding at the interface with the receptor‐binding domain is promising to achieve both preventive and therapeutic effects of coronaviruses. Alternatively, drug‐targeted delivery based on ACE2 receptors can...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.